Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for LYL273 (GCC CAR-T) in Metastatic Colorectal Cancer. The expected timing is based on the latest available company guidance and may change.
11/12/25:- Acquired LYL273; Phase 1 ongoing. Next Phase 1 data update in H1 2026. 03/12/26:- Seven additional mCRC patients treated in U.S. Ph1; no DLTs; 67% ORR, 83% DCR, 8‑month PFS. 05/06/26:- U.S. Ph1 continues; Dose Level 3 dosing started March; safety data H1 2026; outcomes data H2 2026. 06/08/26:- Ph1 safety improved with GI prophylaxis; trial amended to Ph1/2 CARABINER. Ph1 data and FDA meeting expected H2 2026. 08/06/26:- Ph1 safety updated. Trial amended to Ph1/2. Data and FDA meeting expected H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.